• Jianna He, Luke Williamson, Ken Cai, Peter Wong, Allan Sturgess, John Taper, and Nicholas Manolios.
• Department of Rheumatology, Westmead Hospital, Sydney, New South Wales, Australia.
• Intern Med J. 2022 Oct 1; 52 (10): 171717231717-1723.

BackgroundRheumatoid arthritis (RA) is a common autoimmune disease where methotrexate (MTX) is widely used as the first-line therapy. The combination of RA and MTX is associated with lymphoproliferative disorders (LPD). RA patients with Epstein-Barr virus (EBV) have impaired T-lymphocyte function, thus allowing an overgrowth of EBV-positive lymphoblastoid cells. We examined the association of EBV with LPD in immunosuppressed RA patients, particularly those treated with MTX.AimTo review the relationship between RA, EBV-associated LPD and MTX use.MethodsWe reported two cases of RA patients with long-term MTX treatment who subsequently developed EBV-positive LPD, followed by a review of the relevant literature.ResultsCompared with normal population, RA patients have a higher risk of lymphoma, with diffuse large B-cell lymphoma being the most common subtype. MTX withdrawal can lead to lymphoma regression. Other biological therapies, such as abatacept and tocilizumab, are not associated with increased EBV-positive lymphoma diagnosis in RA patients.ConclusionThe association between EBV, lymphoma and MTX highlights the need to consider reducing or stopping MTX in patients who have had stable RA for many years.© 2021 Royal Australasian College of Physicians.

24 keywords...

hide…